The president's state visit comes amid tensions with carmaker Toyota over potential auto tariffs. Trump has repeatedly threatened Japanese and European carmakers with tariffs.Traderead more
Microsoft shares have gained 133% since November 2015, outperforming a tech "basket of unicorns" over that stretch.Technologyread more
Buybacks have gotten a bad rap from both Republicans and Democrats. But stocks would be trading at a massive discount without them.Marketsread more
The IRS is about to release a new draft of Form W-4, which will more closely reflect the changes stemming from the Tax Cuts and Jobs Act. For workers, that means they'll need...Personal Financeread more
The Mega Millions jackpot has spilled over $400 million. It would be the ninth largest winning since the game began in 2002.Personal Financeread more
When commercial real estate investor Manny Khoshbin spent $2.2 million on the fastest production car in the world, he had no idea it would very quickly also become the...Autosread more
Trump was speaking at a meeting of Japanese business leaders in Tokyo during his state visit to Japan on Saturday.Marketsread more
The biggest U.S. gasoline price surge in years is running out of steam just in time for the start of the summer driving season.Energyread more
The federal minimum wage has remained $7.25 per hour since 2009. But several states, and even some companies, have since taken matters into their own hands to pay employees a...Workread more
Stocks rose on Friday, but notched weekly losses as investors worried the U.S.-China trade war is hurting economic growth.US Marketsread more
How much would you pay for a drug that could prolong your life? $1 million? Try 10 times that amount.
The U.K.'s National Health Service (NHS) has been given permission to roll out its most expensive treatment.
The Soliris drug will be used in the treatment of a rare blood disorder and will cost approximately £340,200 per patient during their first year of treatment, which could add up to a whopping overall bill to the government of £10 million ($15.2 million).
The drug, whose trade name is Eculizumab, will help treat a life-threatening, genetic disorder that affects up to 200 Brits. The drug would help patients live an independent life for an extra 25 years.
The National Institute for Health and Care Excellence (NICE), an NHS drug advisory body has approved funding for Eculizumub, to fight the disease dubbed 'aHUS' (atypical Haemolytic Uraemic Syndrome) which affects vital organs such as the brain, heart and kidneys, according to the aHUS Source website.
At the moment, aHUS patients are treated with blood and plasma transfusions, kidney transplants and dialysis.
In response to the announcement, Andrew Dillon, NICE's chief executive said that they were "pleased to be able to recommend Eculizumab for funding" as "aHUS is a very distressing condition that imposes a significant burden both on those with the condition and their carers and families."
NICE stated that in the drug's initial year of usage, the NHS may fork out up to £58 million, which could surge to £82 million five years on - if it accounted for all of its patients receiving treatment.
To combat the cost, NICE recommends further exploration into aHUS and the drug, such as modifying the drug's dosage.
A NICE report published last October suggests that 56 patients are receiving eculizumab under an interim commission policy by the NHS.
NICE proposed that Eculizumab should only be financed "if important conditions are met, including the development of rules for starting and stopping treatment for clinical reasons" said Dillon in the report.